List of Studies ( Metabolite:3E,5E-Tridecadienoic acid)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
|---|---|---|---|---|---|---|---|
| ST001796 | AN002917 | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib | Mesenteric lymph | Mus musculus | Diabetes | Monash Institute of Pharmaceutical Sciences | height |
| ST000310 | AN000490 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | Peak area |
| ST000248 | AN000392 | Metabolic heterogeneity in Glioblastoma | Glioma cells | Human | Cancer | University of Florida | Peak height |
| ST000310 | AN000492 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | Peak height |
| ST000403 | AN000643 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
| ST000539 | AN000819 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
| ST000421 | AN000663 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000421 | AN000664 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000421 | AN000665 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000422 | AN000667 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000422 | AN000668 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000422 | AN000669 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000046 | AN000076 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000046 | AN000077 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000046 | AN000078 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000047 | AN000081 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000047 | AN000083 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
